These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30300440)

  • 41. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
    Rubino CM; Bhavnani SM; Loutit JS; Morgan EE; White D; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
    Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
    J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potency of Meropenem-Vaborbactam in Lung Surfactant.
    Rubio-Aparicio D; Loutit J; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
    Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
    J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study.
    Parker SL; Pandey S; Sime FB; Lipman J; Roberts JA; Wallis SC
    Anal Bioanal Chem; 2019 Nov; 411(29):7831-7840. PubMed ID: 31732787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
    Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection.
    Ho VP; Jenkins SG; Afaneh CI; Turbendian HK; Nicolau DP; Barie PS
    Surg Infect (Larchmt); 2011 Aug; 12(4):325-7. PubMed ID: 21859337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing
    Tumbarello M; Raffaelli F; Cascio A; Falcone M; Signorini L; Mussini C; De Rosa FG; Losito AR; De Pascale G; Pascale R; Giacobbe DR; Oliva A; Farese A; Morelli P; Tiseo G; Meschiari M; Del Giacomo P; Montagnani F; Fabbiani M; Vargas J; Spanu T; Bassetti M; Venditti M; Viale P
    JAC Antimicrob Resist; 2022 Mar; 4(1):dlac022. PubMed ID: 35265842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; De Pascale G; Cascio A; De Rosa FG; Cattelan AM; Oliva A; Saracino A; Bassetti M; Mussini C; Luzzati R; Capone A; Signorini L; Bartoletti M; Sambo M; Sarmati L; Antinori S; Mularoni A; Tascini C; Corona A; Pascale R; Rubino R; Corcione S; Mazzitelli M; Giuliano G; Lovecchio A; Bavaro DF; Meschiari M; Montagnani F; Fabbiani M; De Benedetto I; Antonelli M; Venditti M; Viale P
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae273. PubMed ID: 38854388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae.
    Kulengowski B; Campion JJ; Feola DJ; Burgess DS
    J Antibiot (Tokyo); 2017 Aug; 70(9):974-978. PubMed ID: 28676713
    [No Abstract]   [Full Text] [Related]  

  • 53. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
    Castanheira M; Huband MD; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.
    Munson E; Huband MD; Castanheira M; Fedler KA; Flamm RK
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):324-328. PubMed ID: 29276104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
    Shields RK; McCreary EK; Marini RV; Kline EG; Jones CE; Hao B; Chen L; Kreiswirth BN; Doi Y; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2020 Jul; 71(3):667-671. PubMed ID: 31738396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing
    Gaibani P; Lombardo D; Bussini L; Bovo F; Munari B; Giannella M; Bartoletti M; Viale P; Lazzarotto T; Ambretti S
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34066420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
    Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
    Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
    Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.